This funding supports early-stage translational research activities to identify and characterize potential therapeutic candidates and combination products for HLBS diseases and disorders. It facilitates the transition of basic science discoveries into viable diagnostic and therapeutic candidates cleared for human testing, excluding clinical trials. The initiative aims to develop translational researchers skilled in product development and entrepreneurship, advancing projects to meet criteria for further preclinical development.
Eligible applicants include a wide range of U.S. entities such as city, county, and state governments, small businesses, nonprofits, tribal governments and organizations, and institutions of higher education. Specific eligibility details should be confirmed with the funding agency.
